CSIMarket Company Name, Ticker, Competitors, else..
 
Prothena Corporation Public Limited Company  (NASDAQ: PRTA)
Other Ticker:  
 
 
Price: $12.9700 $0.10 0.777%
Day's High: $12.99 Week Perf: -5.6 %
Day's Low: $ 12.54 30 Day Perf: -14.95 %
Volume (M): 870 52 Wk High: $ 26.36
Volume (M$): $ 11,277 52 Wk Avg: $18.56
Open: $12.72 52 Wk Low: $11.70



 Market Capitalization (Millions $) 699
 Shares Outstanding (Millions) 54
 Employees 184
 Revenues (TTM) (Millions $) 135
 Net Income (TTM) (Millions $) -122
 Cash Flow (TTM) (Millions $) -149
 Capital Exp. (TTM) (Millions $) 0

Prothena Corporation Public Limited Company
Prothena Corporation Public Limited Company is a biotechnology company that specializes in developing and commercializing therapies for neurodegenerative diseases. The company focuses on creating drugs that target the misfolding and accumulation of proteins, which are believed to play a role in diseases like amyloidosis, Parkinson's disease, and Alzheimer's disease. Prothena's research and development efforts are centered around antibody-based therapies, with the goal of preventing or slowing the progression of these diseases. The company is headquartered in Dublin, Ireland, and is publicly traded on the NASDAQ stock exchange.


   Company Address: 77 Sir John Rogerson?s Quay, Block C Dublin 2, 0
   Company Phone Number: 236-2500   Stock Exchange / Ticker: NASDAQ PRTA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -2.08%    
BMY        1.8% 
LLY        1.55% 
SNY   -3.43%    
TEVA   -3.65%    
VTRS   -1.08%    
• View Complete Report
   



Prothena Corporation Public Limited Company

Dramatic Decline: Prothena Corporation Sees Sharp Drop in Earnings During Q1 2024



The stock market is known for its unpredictability and occasional setbacks. In such a landscape, it becomes crucial for investors to remain optimistic and focused on long-term growth prospects. Prothena Corporation Public Limited Company, a leading biotechnology firm, recently reported its first-quarter earnings for 2024 with disappointing figures. However, let us venture beyond the initial numbers and explore the potential opportunities that lie ahead.
Revenue Plunge and Share Shortfall:
Prothena Corporation faced tumultuous first-quarter results in 2024 as its revenue plummeted by a staggering 97.695%. The company's revenue was a mere $0.05 million, reflecting a significant decline from the previous period. The share shortfall also widened from $-1.12 to $-1.34 compared to the corresponding period a year prior. While these figures might appear discouraging at first glance, a deeper analysis unveils opportunities for investors.
Prothena Corporation Public Limited Company

2. Prothena Corporation Public Limited Company Faces Significant Decline in Share Price and Financial Performance

Prothena Corporation Public Limited Company has been experiencing a downward trend in its share price over the past few months. The shares went down by -13.3% in the trailing 30 days, bringing the share price to -15.73% in the past 90 days. Additionally, the shares are currently trading only 15.4% above its 52-week low.
Looking at the financial results for the October to December 31, 2023 interval, the company slipped into a shortfall of $-1.12 per share compared to $0.13 a year prior. The earnings per share (EPS) fell from $0.38 per share from the preceding reporting season. The revenue also took a hit, falling sharply by -99.367% to $0.32 million from $49.92 million in the same reporting season a year prior, with sequential revenue tumbling by -99.628% from $84.87 million.
Prothena Corporation Public Limited Company

Prothena Corporation Records Exponential Revenue Surge of 5494%, Setting Stage for Prominence in Healthcare Sector

Prothena Corporation Public Limited Company, a leading corporation in the healthcare sector, recently released its financial results for the third quarter of 2023. The report indicates significant improvements across various key financial metrics, highlighting the company's successful turnaround and demonstrating its potential for future growth.
One of the most astonishing figures in the report is the staggering increase in revenue. Prothena Corporation's revenue skyrocketed by an impressive 5494.331% year on year, reaching an impressive $84.87 million in the third quarter of 2023. This substantial growth indicates a strong market demand for the company's products or services, potentially positioning Prothena Corporation as a prominent player in the industry.
Prothena Corporation Public Limited Company

Prothena Corporation Shatters Industry Norms with 206.326% Revenue Surge, Triumphs Over Major Pharmaceutical Contemporaries



Prothena Corporation Public Limited Company recently announced its financial results for the most recent fiscal period, revealing both impressive revenue growth and an increased deficit per share. While the year-to-date performance of the company's shares remains positive, it is essential to analyze the impact of these results on Prothena Corporation's future prospects.
1. Robust Revenue Growth:
Prothena Corporation reported a remarkable year-on-year revenue increase of 206.326%, reaching $4.02 million in the most recent fiscal period. This growth outpaced that of its sector peers, as the Major Pharmaceutical Preparations sector expressed a revenue advance of only 5.28% during the same period. The company's ability to outperform its peers on the top-line side is undoubtedly encouraging.
Prothena Corporation Public Limited Company

Prothena Corporation Public Limited Company Rocks Q1 Earnings: Revenue Soars, Deficit Grows

The stock market has been witnessing a lot of excitement lately, with many companies putting out their earnings reports for the first quarter of 2023. Among these, one name that has garnered significant attention is Prothena Corporation Public Limited Company (PRTA).
The company reported an increase in the shortfall per share during the first quarter of 2023, as compared to the earnings from a year prior. However, what is interesting to note is that the revenue grew significantly by 88.118% to $2.17 million, as compared to the same reporting season in the year prior. This is a strong indication that the company is heading in the right direction, despite the shortfall in earnings.






Prothena Public Limited's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com